NF1功能缺失是小叶乳腺癌内分泌治疗获得性耐药的机制
研究对336例原发性小叶乳腺癌(ILC)和485例雌激素受体(ER)阳性浸润性导管癌(IDC)组织,以及180例ILC和191例ER阳性IDC患者的转移活检标本进行基因组分析;发现NF1改变仅富集于ILC转移灶,与ESR1突变互斥,并在获得性耐药中出现;体外模型显示NF1敲低赋予4-羟基他莫昔芬下的生长优势;ILC转移灶肿瘤突变负荷较原发ILC或转移IDC显著升高。
要点
- NF1改变仅富集于小叶乳腺癌转移灶,与原发灶相比。
- NF1改变与ESR1突变互斥(OR=0.24,P<0.027),在ctDNA中常为多克隆。
- ILC转移灶TMB较原发ILC或转移IDC显著升高(8.9%>20突变/Mb,P<0.001)。
核心结论
- 本研究识别NF1改变特异性地富集于小叶乳腺癌转移灶。
- 与ESR1改变互斥、复发ctDNA中多克隆及新发获得提示NF1缺失在内分泌治疗耐药中起作用。
- 由于NF1缺失导致RAS/RAF激酶激活,患者可能从匹配的抑制剂中获益。
- 对于独立的一部分小叶乳腺癌转移患者,TMB较原发小叶乳腺癌升高,提示可能从免疫检查点抑制剂中获益。
研究设计与样本
- 对336例原发性富集的小叶乳腺癌活检组织和485例ER阳性浸润性导管癌组织,以及180例小叶乳腺癌和191例ER阳性浸润性导管癌患者的转移活检标本进行基于杂交捕获的综合基因组分析。
- 检测短变异、插入缺失、拷贝数变异和重排,覆盖最多395个癌症相关基因。
- 采用CDH1突变ER阳性乳腺癌体外模型进行NF1敲低实验。
主要发现
- ESR1改变在ILC和IDC转移灶中均较乳腺标本富集,而NF1改变仅在ILC转移灶中富集。
- NF1改变主要为杂合性缺失(11/14,79%),与ESR1突变互斥(比值比=0.24,P<0.027),在ctDNA检测中常为多克隆。
- 配对标本评估显示NF1改变在获得性耐药背景下出现。
- CDH1突变ER阳性乳腺癌体外模型显示NF1敲低在4-羟基他莫昔芬存在下赋予生长优势。
- ILC转移灶肿瘤突变负荷较原发ILC或转移IDC显著升高(8.9%>20突变/Mb;P<0.001)。
关键数值与推荐
- NF1改变与ESR1突变互斥的比值比=0.24,P<0.027。
- NF1改变中杂合性缺失占11/14(79%)。
- TMB>20突变/Mb在ILC转移灶中占8.9%,P<0.001。
- TMB高的ILC转移灶中APOBEC特征占14/16(88%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive lobular carcinoma (ILC) as a disease entity distinct from invasive ductal carcinoma (IDC) has merited focused studies of the genomic landscape, but those to date are largely limited to the assessment of early-stage cancers. Given that genomic alterations develop as acquired resistance to endocrine therapy, studies on refractory ILC are needed. PATIENTS AND METHODS: Tissue from 336 primary-enriched, breast-biopsied ILC and 485 estrogen receptor (ER)-positive IDC and metastatic biopsy specimens from 180 ILC and 191 ER-positive IDC patients was assayed with hybrid-capture-based comprehensive genomic profiling for short variant, indel, copy number variants, and rearrangements in up to 395 cancer-related genes. RESULTS: Whereas ESR1 alterations are enriched in the metastases of both ILC and IDC compared with breast specimens, NF1 alterations are enriched only in ILC metastases (mILC). NF1 alterations are predominantly under loss of heterozygosity (11/14, 79%), are mutually exclusive with ESR1 mutations [odds ratio = 0.24, P < 0.027] and are frequently polyclonal in ctDNA assays. Assessment of paired specimens shows that NF1 alterations arise in the setting of acquired resistance. An in vitro model of CDH1 mutated ER-positive breast cancer demonstrates that NF1 knockdown confers a growth advantage in the presence of 4-hydroxy tamoxifen. Our study further identified a significant increase in tumor mutational burden (TMB) in mILCs relative to breast ILCs or metastatic IDCs (8.9% >20 mutations/mb; P < 0.001). Most TMB-high mILCs harbor an APOBEC trinucleotide signature (14/16; 88%). CONCLUSIONS: This study identifies alteration of NF1 as enriched specifically in mILC. Mutual exclusivity with ESR1 alterations, polyclonality in relapsed ctDNA, and de novo acquisition suggest a role for NF1 loss in endocrine therapy resistance. Since NF1 loss leads to RAS/RAF kinase activation, patients may benefit from a matched inhibitor. Moreover, for an independent subset of mILC, TMB was elevated relative to breast ILC, suggesting possible benefit from immune checkpoint inhibitors.
引用
- Sokol ES, Feng YX, Jin DX, et al. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. Ann Oncol. 2019. PMID: 30423024. doi:10.1093/annonc/mdy497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。